Europe
Reveal Genomics' HER2DX Assay De-Escalates Early Breast Cancer Treatment in Real-World Study
Premium
The observational study measured how physicians changed treatment plans after seeing HER2DX results and how patients did on the new plans.
Anixa Biosciences Nabs Option to Develop Cancer Vaccines With Verdi Solutions
If Anixa exercises its rights, Verdi and Anixa will collaborate on trials in the US, while Verdi will continue developing personalized vaccines in Europe.
Angle Hoping to Continue Developing Parsortix HER2 CTC Assay With BlissBio, Eisai
Although Eisai decided not to option a HER2-targeted drug under a deal with BlissBio, Angle wants to keep working with the firms to advance its CTC technology.
Autolus Reports Steady Progress for Aucatzyl's US Launch, Anticipating European Approvals in 2025
The firm also said its partner BioNTech won't exercise its option rights for the CD19- and CD22-directed CAR T-cell therapy candidate AUTO1/22.
Novartis to Seek Approval for Intrathecal SMA Gene Therapy in Children, Young Adults in Early 2025
An intravenous form of the gene therapy is already approved and sold as Zolgensma in the US for patients less than 2 years of age.
Mar 13, 2025
Mar 11, 2025